Related Experiment Video
Updated: Jun 16, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation
Chao Ding1, Ying Wu2, Chaochao Zhan1
1Key Laboratory of Basic and Application Research of Beiyao (Heilongjiang University of Chinese Medicine), Ministry of Education, Harbin 150040, China.
Abstract:
Inflammation is a protective mechanism against endogenous and exogenous pathogens. It is a typical feature of numerous chronic diseases and their complications. Keap1 is an essential target in oxidative stress and inflammatory diseases. Among them, the Keap1-Nrf2-ARE pathway (including Keap1-Nrf2-HO-1) is the most significant pathway of Keap1 targets, which participates in the control of inflammation in multiple organs (including renal inflammation, lung inflammation, liver inflammation, neuroinflammation, etc.). Identifying new Keap1 inhibitors is crucial for new drug discovery. However, most drugs have specificity issues as they covalently bind to cysteine residues of Keap1, causing off-target effects. Therefore, direct inhibition of Keap1-Nrf2 PPIs is a new research idea. Through non-electrophilic and non-covalent binding, its inhibitors have better specificity and ability to activate Nrf2, and targeting therapy against Keap1-Nrf2 PPIs has become a new method for drug development in chronic diseases. This review summarizes the members and downstream genes of the Keap1-related pathway and their roles in inflammatory disease models. In addition, we summarize all the research progress of anti-inflammatory drugs targeting Keap1 from 2010 to 2024, mainly describing their biological functions, molecular mechanisms of action, and therapeutic roles in inflammatory diseases.
Insights
New Keap1 inhibitors targeting the Keap1-Nrf2 pathway offer improved specificity for treating inflammatory diseases. This approach avoids off-target effects common with traditional covalent inhibitors, paving the way for novel drug development.
Area of Science:
- Molecular Biology
- Pharmacology
- Immunology
Background:
- Inflammation is a key factor in chronic diseases.
- The Keap1-Nrf2-ARE pathway is crucial for controlling inflammation.
- Current Keap1 inhibitors often cause off-target effects due to covalent binding.
Purpose of the Study:
- To review the Keap1-Nrf2-ARE pathway and its role in inflammation.
- To summarize research on Keap1 inhibitors from 2010-2024.
- To explore novel non-covalent Keap1 inhibitors for drug discovery.
Main Methods:
- Literature review of Keap1-Nrf2 pathway research.
- Analysis of anti-inflammatory drug mechanisms targeting Keap1.
- Summary of therapeutic roles in inflammatory disease models.
Main Results:
- The Keap1-Nrf2-ARE pathway is vital in multiple organ inflammation.
- Non-covalent Keap1 inhibitors show promise for targeted therapy.
- Research highlights improved specificity and Nrf2 activation.
Conclusions:
- Targeting Keap1-Nrf2 protein-protein interactions (PPIs) is a promising therapeutic strategy.
- Non-covalent inhibitors offer enhanced specificity and reduced side effects.
- This review provides a comprehensive overview of Keap1-targeted anti-inflammatory drug development.
Related Concept Videos
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of the Unfolded Protein Response
The Extrinsic Apoptotic Pathway

